

Nivel FluCov: Influenza-COVID-19 Activity Report #2

17 March 2025


Seasonal Influenza

High activity in Denmark, declining trends in the rest of the Northern Hemisphere

- North America and Europe:** Influenza activity declined in Europe, as the peak in influenza activity has passed in most countries. Activity however keeps increasing in Denmark (medium activity: 34.8% positivity, local data reports a small decline to 32%). Activity in France and the UK is at very low levels (<10%), in Spain at low levels (13.7%) and moderate (25.5%) in Italy. In Germany, activity is decreasing but remains high (46.1%). In the US, influenza activity continued to decrease to 16.1% positivity.
- Asia:** Overall influenza activity in China decreased further at very low levels (<10% positivity), with low activity (13.3%) in Southern China.
- Southern Hemisphere:** Influenza activity was below baseline in most countries in the Southern Hemisphere.
- Severity:** The current influenza season is considered intense in both the US and EU. CDC have classified this as the first high severity season across all ages since 2017/18. Hospital admissions in the EU continue to decrease in all age groups in most reporting countries.
- Circulating virus:** Globally, of sequenced samples, influenza A(H1N1)pdm09 was the predominant virus type, followed by A(H3N2) and B/Victoria. This season up to week 10, influenza A(H1N1)pdm09 dominated circulation in China (99%), while a mix of influenza A(H1N1)pdm09 and A(H3N2) circulated in the US (1:1). In the EU, dominance varied across countries: of subtyped viruses, overall influenza A and B circulation was around 3:1; influenza A(H1N1):A(H3N2) circulation was 2:1.
- Vaccine match:** Based upon antigenic characterization (wk10), the US and UK report a good match (100% 'well recognised'/'similar') for influenza A(H1N1)pdm09 and B/Victoria and a partial match (57-77% 'well-recognised'/'similar') for influenza A(H3N2). Estimates of current mid-season influenza VE in Europe, France and China range from 32% to 58% overall, with greater protection against influenza B than A.
- Influenza Viruses of Pandemic Potential:** No human IVPP infections were reported in the past two weeks.
- SARS-CoV-2 activity:** Low globally in week 9, with a few exceptions of elevated activity reported in Temperate South America.

Positive Influenza tests (%)


█ Season 2024/2025
 █ Season 2023/2024
 █ Season 2022/2023
 █ Average of Pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



Data reported for week
2025-10

Influenza viruses with pandemic potential

Global IVPP cases per month (starting January 2023)



AU = Australia, BR = Brazil, CA = Canada, CL = Colombia, CN = China, EC = Ecuador, ES = Spain, GB = United Kingdom, GH = Ghana, HK = Hong Kong, IN = India, KH = Cambodia, MX = Mexico, NL = Netherlands, TW = Taiwan, US = United States, VN = Vietnam

New cases are outlined in yellow

New since 3 March

No new IVPP cases were reported in the past two weeks.

For avian influenza virus infections in animals, please see: [Global AIV with Zoonotic Potential \(fao.org\)](https://www.fao.org/) [last updated 27 February 2025].

Seasonal influenza global overview: 17 March 2025

Global circulation: In the Northern hemisphere, influenza activity decreased or remained the same in most countries. Activity remained elevated in North America, Central America and the Caribbean, Tropical South America, Northern and Western Africa, Europe and Asia. In the Southern hemisphere, elevated activity was observed in a few countries in Eastern Africa and South-East Asia, and Oceania.

Northern Hemisphere				
Country/ region	Week	Indicator	Info	Trend
EU	10	Predominant virus type	Co-circulation of A(H1N1)pdm09, A(H3N2) and B/Vic influenza viruses	↓
		Influenza activity	Intense seasonal activity, passed peak	
		% positive tests	Pooled: 35%, median: 39%	
		SARI influenza positive	Pooled: 15%, median: 12%	
		Mortality (EuroMOMO)	Increased levels of mortality, driven by high mortality in several countries	
England	10	Predominant virus type	Mainly influenza A(H1N1)pdm09, recently increase in influenza B positivity rates	<10%
		Influenza activity	Low activity levels	
		% positive tests	9.5%	
		Hospitalization rate	3.05 per 100,000	
USA	10	Predominant virus type	Cocirculation of A(H1N1)pdm09 & A(H3N2)	↓
		Influenza activity	Remains elevated nationally, but has decreased for four consecutive weeks	
		% positive tests	16.1%	
		Hospitalization rate	3.7 per 100,000	
		Mortality	1.9% of deaths attributed to influenza	
Canada	10	Predominant virus type	Influenza A(H1N1)pdm09	↓
		Influenza activity	Decrease on national level	
		% positive tests	24%	
		Hospitalization rate	5.0 per 100,000	
		Mortality	200 deaths since 25 August 2024	
China	10	Predominant virus type	A(H1N1)pdm09	<10%
		Influenza activity	Decrease in Southern and Northern provinces	
Southern Hemisphere				
Brazil	9	Predominant virus type	Influenza B/Victoria	<10%
		Influenza activity	Below epidemic threshold	
		% positive tests	2.6%	
Australia	5-8	Predominant virus type	Influenza A(H1N1)pdm09	<10%
		Influenza activity	Low at interseasonal levels	
		% positive tests	5.2% WHO FluNet week 10	
		Hospitalizations	102 adults in 2025	
		Mortality rate	No update	
South Africa	10	Predominant virus type	Influenza A	<10%
		Influenza activity	Baseline	
		% positive tests	3.4% (4/116 detections)	
		Hospitalizations	8 (30 Dec 2024 – 9 March 2025)	

↑ increase; → stable; ↓ decrease

SARS-CoV-2 global overview: 17 March 2025

Global circulation: Globally, SARS-CoV-2 activity remained low across reporting countries with a few exceptions of elevated activity reported in Temperate South America.

Northern Hemisphere				
Country/region	Week	Indicator	Info	Trend
EU	10	Detections	At very low level	→
		% positive tests	Pooled: 2.1%, median: 0.2%	
		SARI SARS-CoV-2 positive	Pooled: 2.2%, median: 2%	
		Mortality (EuroMOMO)	Increased levels of mortality, driven by high mortality in several countries	
England	10	Detections	Circulating at baseline level	→
		% positive tests	3.3%	
		Hospitalizations	1.29 per 100,000	
		Mortality	67 (7 days up to 28 Feb 2025)	
USA	10	% positive tests	3.8%	↓
		Hospitalizations	2.3 per 100,000	
		Mortality	1.0% of all deaths	
Canada	10	Detections/activity	Decreasing or stable indicators	↓
		% positive tests	2.5%	
		Hospitalizations	1.1 per 100,000	
		Mortality	1761 deaths since 25 August 2024	
China	9	Detections	0 cases reported (28 days up to 2 March)	→
		% positive tests	-	
Southern Hemisphere				
Brazil	9	Detections	Remained elevated	→
		% positive tests	13.6%	
Australia	5-8	Detections	Decreasing	↓
		% positive tests	3.5%	
		Hospitalizations	223 adults in 2025	
		Mortality	No update	
South Africa	10	Detections	Low detection rate	→
		% positive tests	4.3% (5/116 detections)	
		Hospitalizations	34 (30 Dec 2024 – 9 March 2025)	

↑ increase; → stable; ↓ decrease; → stable at base level

Data sources & details FluCov influenza and COVID-19 activity report

Percentage positive graphs (via CERP - [CERP - EPI Live! Flu](#))

China:	China CDC	Germany & Italy:	WHO FluNET (sentinel)
US:	FluView (Clinical Laboratories)	All others:	WHO FluNet (non-sentinel)
Spain:	ERVISS (sentinel)	Vaccine match:	US (CDC), EU (ERVISS)

Influenza Viruses with Pandemic Potential

- [ProMED](#)
- [Disease Outbreak News | WHO](#)
- <http://outbreaknewstoday.com/>
- [Homepage | CIDRAP](#)
- [ECDC Weekly threats reports \(CDTR\) \(europa.eu\)](#)

Seasonal influenza and SARS-CoV-2

Global

- [Global Influenza Programma - Influenza update | WHO](#) (#517, 12 March 2025)
- [FluCov Dashboard | Nivel](#)

Europe

- [ERVISS | ECDC](#) (W10)
- [EuroMOMO](#) (W10)
- [National flu and COVID-19 surveillance reports: 2024 to 2025 season | UKHSA](#) (W11)
- [COVID-19 | UKHSA data dashboard](#) (13 March 2025)

Americas

- [FluView | FluView | CDC](#) (EW10)
- [COVID Data Tracker | CDC](#) (14 March 2025)
- [Overview: Canadian respiratory virus surveillance report \(FluWatch+\) — Canada.ca](#) (EW10)
- [Respiratory Viruses weekly report | PAHO - WHO](#) (EW9)

Western Pacific

- [Weekly Report | Chinese National Influenza Center](#) (W10)
- [Seasonal influenza \(who.int\)](#) (12 March 2025)
- [COVID-19 situation reports | WHO Western Pacific](#) (14 March 2025)
- [Australian Respiratory Surveillance Reports – 2024 | Australian Government Department of Health and Aged Care](#) (W5-8)

Africa

- [Weekly respiratory pathogens surveillance report week | NICD](#) (W10)

A Nivel publication

Boudewijns, B., Heemskerk, S., Heuvel, L. van, Del Riccio, M., Caini, S., Schneeberger, C. [Nivel FluCov: Influenza-COVID-19 Activity Report #2: 17 March 2025](#). Netherlands, Utrecht: Nivel, 2025

Websites for more information

Project Website: <https://www.nivel.nl/en/fluov>

FluCov Dashboard: <https://www.nivel.nl/en/fluov-dashboard>

Funding

The Nivel FluCov project is funded by Sanofi.